309 results on '"Burman, Joachim"'
Search Results
2. Levels of inflammatory cytokines MCP-1, CCL4, and PD-L1 in CSF differentiate idiopathic normal pressure hydrocephalus from neurodegenerative diseases
3. Image-derived input functions from dynamic 15O–water PET scans using penalised reconstruction
4. Cerebrospinal fluid mtDNA concentrations are increased in multiple sclerosis and were normalized after intervention with autologous hematopoietic stem cell transplantation
5. Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee
6. Evoked potentials after autologous hematopoietic stem cell transplantation for multiple sclerosis
7. COVID-19–Related Enhancement for the COMBAT-MS Study
8. Comparing the Safety and Effectiveness of Different Medicines to Treat Multiple Sclerosis – The COMBAT-MS Study
9. Experiences in implementing immunopsychiatry in real life
10. Disease phenotype prediction in multiple sclerosis
11. Predictors of patient-reported fatigue symptom severity in a nationwide multiple sclerosis cohort
12. Cerebrospinal fluid and plasma concentrations of the inflammatory marker sCD27 in a large surgical population
13. Biomarkers of demyelination and axonal damage are decreased after autologous hematopoietic stem cell transplantation for multiple sclerosis
14. Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial
15. Distribution of five clinically important neuroglial proteins in the human brain
16. Evaluation of polarity switching for untargeted lipidomics using liquid chromatography coupled to high resolution mass spectrometry
17. Effectiveness of autologous haematopoietic stem cell transplantation versus natalizumab in progressive multiple sclerosis.
18. Comparing the Safety of Medicines to Treat MS during the COVID-19 Pandemic
19. Conformal prediction enables disease course prediction and allows individualized diagnostic uncertainty in multiple sclerosis
20. Experiences of being treated with autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: A qualitative interview study
21. Experiences of being treated with autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis : A qualitative interview study
22. Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapy
23. Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden : an observational cohort study
24. COMBAT-MS : A Population-Based Observational Cohort Study Addressing the Benefit-Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab
25. An exploratory study of the damage markers NfL, GFAP, and t-Tau, in cerebrospinal fluid and other findings from a patient cohort enriched for suspected autoimmune psychiatric disease.
26. Antibody‐positive autoimmune encephalitis and paraneoplastic neurological syndrome: A Swedish case series.
27. Damage markers in cerebrospinal fluid and other findings from a patient cohort enriched for suspected autoimmune psychiatric disease
28. Metabolic drift in the aging nervous system is reflected in human cerebrospinal fluid
29. Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis diseasemodulating therapy.
30. Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: an observational cohort study
31. CSF Concentrations of CXCL13 and sCD27 Before and After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis
32. Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapy
33. Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of relapsing-remitting multiple sclerosis patients
34. Chapter 12 - Hematopoietic stem cell transplantation for neuromyelitis optica spectrum disorder. Can immune tolerance be reestablished?
35. Chapter 13 - Hematopoietic stem cell transplantation (HSCT) for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): Is it CIDP?
36. Chapter 15 - Autologous hematopoietic stem cell transplantation for pediatric autoimmune neurologic disorders
37. Anti-Müllerian hormone and pregnancy after autologous hematopoietic stem cell transplantation for multiple sclerosis
38. Antibody-Positive Autoimmune Encephalitis and Paraneoplastic Neurological Syndrome: Epidemiology and Outcome of Neuronal Antibody Testing in Sweden
39. CNS damage biomarkers in cerebrospinal fluid and other findings from a patient cohort enriched for suspected autoimmune psychiatric disease
40. Anti-Müllerian hormone and pregnancy after autologous hematopoietic stem cell transplantation for multiple sclerosis
41. Image-derived input functions from dynamic O-15-water PET scans using penalised reconstruction
42. Cerebrospinal fluid cytokines after autologous haematopoietic stem cell transplantation and intrathecal rituximab treatment for multiple sclerosis
43. Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of relapsing-remitting multiple sclerosis patients
44. CSF Concentrations of CXCL13 and sCD27 Before and After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis.
45. Antibodies from serum and CSF of multiple sclerosis patients bind to oligodendroglial and neuronal cell-lines
46. Antibody-Positive Autoimmune Encephalitis and Paraneoplastic Neurological Syndrome : Epidemiology and Outcome of Neuronal Antibody Testing in Sweden
47. Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapy
48. Levels of inflammatory cytokines MCP-1, CCL4, and PD-L1 in CSF differentiate idiopathic normal pressure hydrocephalus from neurodegenerative diseases
49. Plasma neurofilament light chain is elevated after transcatheter aortic valve implantation
50. Improved clinical outcomes in patients treated with Natalizumab for at least 11 years - Real-world data from a Swedish national post-marketing surveillance study (IMSE 1)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.